Optimization of Immunotherapy Strategies Based on Spatiotemporal Heterogeneity of Tumour‐Associated Tissue‐Resident Memory T Cells
Immunology · 2025-06 · 175 (2) · 123-133
DOI: 10.1111/imm.13924 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 20.03.2025. Verfasst von Yile Shang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Neoplasms, Immunotherapy, Memory T Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Tissue‐resident memory T cells (TRMs) reside in peripheral tissues and provide rapid immune defence against local infection and tumours. Tumour‐associated TRMs share common tissue‐resident features and formation mechanisms, representing some unique subsets of tumour‐infiltrating lymphocytes (TILs). However, differences in the tumour microenvironment(TME) and tumour evolution stage result in TRMs exhibiting temporal and spatial heterogeneity of phenotype and function not only at different stages, before and after treatment, but also between tumours originating from different tissues, primary and metastatic cancer, and tumour and adjacent normal tissue. The infiltration of TRMs is often associated with immunotherapy response and favourable prognosis; however, due to different definitions, it has been shown that some subtypes of TRMs can also have a negative impact. Therefore, it is crucial to precisely characterise the TRM subpopulations that can influence the therapeutic efficacy and clinical prognosis of various solid tumours. Here, we review the spatiotemporal heterogeneity of tumour‐associated TRMs, as well as the differences in their impact on clinical outcomes. We also explore the relationship between TRMs and immune checkpoint blockade (ICB) and TIL therapy, providing insights into potential new targets and strategies for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Radiology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Weiqin Jiang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Shang, Y., He, Y., Zhang, X., He, W., Hua, H., Ye, F., Zhou, X., Li, Y., Zhong, W., Wu, G., & Jiang, W. (2025). Optimization of Immunotherapy Strategies Based on Spatiotemporal Heterogeneity of Tumour‐Associated Tissue‐Resident Memory T Cells. Immunology, 175(2), 123-133. https://doi.org/10.1111/imm.13924
Vancouver
Shang Y, He Y, Zhang X, He W, Hua H, Ye F, et al. Optimization of Immunotherapy Strategies Based on Spatiotemporal Heterogeneity of Tumour‐Associated Tissue‐Resident Memory T Cells. Immunology. 2025;175(2):123-133. doi:10.1111/imm.13924
BibTeX
@article{Shang2025,
author = {Shang, Yile and He, Yinjun and Zhang, Xiang and He, Wenguang and Hua, Hanju and Ye, Feng and Zhou, Xile and Li, Yandong and Zhong, Weixiang and Wu, Guosheng and Jiang, Weiqin},
title = {Optimization of Immunotherapy Strategies Based on Spatiotemporal Heterogeneity of Tumour‐Associated Tissue‐Resident Memory T Cells},
journal = {Immunology},
year = {2025},
volume = {175},
number = {2},
pages = {123--133},
doi = {10.1111/imm.13924}
}
EUVIMED